Diagnostic and prognostic potential of the novel biomarker nuclear cap binding protein subunit 2 (NCBP2) in colon adenocarcinoma

Abstract

Background: Colon adenocarcinoma (COAD) is an incurable malignancy and the third most common tumor worldwide. Advances in biomarkers screening have greatly contributed to explore the new diagnostic and prognostic biomarkers for the early detection and prognostic of COAD. However, the heterogeneityspecific nature of COAD in patients of different cancer stages, different races, genders and age are still the major challenge to clinical treatment.Methods: Gene expression, copy number (CN), and dependency score (DS) data were obtained from the Cancer Cell Line Encyclopedia (CCLE), and linear regression analyses were performed using R language. We conducted receiver operating characteristic (ROC) curve analysis and compared the area under the ROC curve area under the curve (AUC) values to evaluate the sensitivity and specificity of nuclear cap binding protein subunit 2 (NCBP2) for the diagnosis of COAD in The Cancer Genome Atlas (TCGA) database. Survival analysis was performed in the distinct NCBP2 expression groups. In vitro experiments and bioinformatics analysis were used to investigate the molecular mechanisms of NCBP2 in COAD and its biological roles. A Connectivity Map (Cmap) was used to identify potential small molecule targeted drugs for NCBP2 in COAD.Results: Through the linear regression analysis of DS, CN, and gene expression, we determined that NCBP2 met our criteria. The mean AUC of the ROC curve of NCBP2 was 0.940±0.050. Survival analysis showed that high NCBP2 expression was associated with a worse prognosis [hazard ratio (HR) =1.98, P<0.007]. NCBP2 knockdown inhibited COAD cell proliferation and caused G0/G1 phase arrest in COAD cells.Conclusions: NCBP2 was the novel diagnostic and prognostic biomarker of in COAD. Our research had implications for the treatment of colon cancer.

The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling

“…In our study, we reveal that NCBP2 is significantly upregulated in PDAC and associated with poor prognosis in PDAC patients. Although there are several reports revealing the high expression of NCBP2 in different cancer types, its specific function and related molecular mechanisms in cancer development are still unclear [39,40]. Here, we reveal that NCBP2 increases the translation of c-JUN in an m 7 G-dependent manner to activate MEK/ERK signaling, thereby promoting PDAC progression.…”

m7G‐related genes—NCBP2 and EIF4E3 determine immune contexture in head and neck squamous cell carcinoma by regulating CCL4/CCL5 expression

“…Transcribed mRNAs are bound and escorted to the cytoplasm by the CBC for further translation and modification 15,16 . It is, therefore, understandable that NCBP2 is highly expressed in various tumors, including lung cancer, and is associated with their poor prognosis 45,46 . However, whether NCBP2 has selectivity in term of mRNA translation is still largely unknown.…”

“…15,16 It is, therefore, understandable that NCBP2 is highly expressed in various tumors, including lung cancer, and is associated with their poor prognosis. 45,46 However, whether NCBP2 has selectivity in term of mRNA translation is still largely unknown. EIF4E1 functions based on m7G cap structure in cytoplasm.…”

Comprehensive bioinformatics analysis of FXR1 across pan-cancer: Unraveling its diagnostic, prognostic, and immunological significance

“…Several cancers have been linked to this gene, including ovarian carcinoma, colon cancers, and lung cancers. [34][35][36] In addition to inhibiting apoptosis, modulating signaling pathways, and responding to DNA damage, NCBP2 plays a critical role in cancer cell cycle regulation. [34] XPO1 is the exclusive exporter of various proteins that suppress tumor growth and regulate the cell cycle.…”